Hospital acquired infections are a significant problem for the NHS with the superbugs MRSA and C. difficile costing the health service £1Bn each year.
This exhibit outlines current BBSRC-funded research into these superbugs which could lead to new ways of overcoming their resistance to drug therapies. It profiles some recently established companies that are using their research expertise to help develop new ways of combating superbug infections.
Patrick Middleton, Head of Engagement
tel: 01793 413368
fax: 01793 413382